Lisa A Newman1, Azadeh Stark1,2, Dhanajay Chitale2, Margaret Pepe3, Gary Longton3, Maria J Worsham4, S David Nathanson1, Patricia Miller5, Jessica M Bensenhaver1, Erica Proctor1, Monique Swain1, Christos Patriotis6, Paul F Engstrom7. 1. Breast Oncology Program, Department of Surgery, International Center for the Study of Breast Cancer Subtypes, Henry Ford Health System, Detroit, Michigan. 2. Breast Oncology Program, Department of Pathology, Henry Ford Health System, Detroit, Michigan. 3. Department of Biostatistics and Biomathematics, Fred Hutchinson Comprehensive Cancer Center, Seattle, Washington. 4. Breast Oncology Program, Department of Otolaryngology, Henry Ford Health System, Detroit, Michigan. 5. Breast Oncology Program, Department of Radiology, Henry Ford Health System, Detroit, Michigan. 6. Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland. 7. Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Abstract
IMPORTANCE: Compared with white American (WA) women, African American (AA) women have a 2-fold higher incidence of breast cancers that are negative for estrogen receptor, progesterone receptor, and ERBB2 (triple-negative breast cancer [TNBC]). Triple-negative breast cancer, compared with non-TNBC, likely arises from different pathogenetic pathways, and benign breast disease (BBD) predicts future non-TNBC. OBJECTIVE: To determine whether AA identity remains associated with TNBC for women with a prior diagnosis of BBD. DESIGN, SETTING, AND PARTICIPANTS: This study is a retrospective analysis of data of a cohort of 2588 AA and 3566 WA women aged between 40 and 70 years with a biopsy-proven BBD diagnosis. The data-obtained from the Pathology Information System of Henry Ford Health System (HFHS), an integrated multihospital and multispecialty health care system headquartered in Detroit, Michigan-include specimens of biopsies performed between January 1, 1994, and December 31, 2005. Data analysis was performed from November 1, 2015, to June 15, 2016. MAIN OUTCOMES AND MEASURES: Subsequent breast cancer was stratified on the basis of combinations of hormone receptor and ERBB2 expression. RESULTS: Case management, follow-up, and outcomes received or obtained by our cohort of 2588 AA and 3566 WA patients were similar, demonstrating that HFHS delivered care equitably. Subsequent breast cancers developed in 103 (4.1%) of AA patients (mean follow-up interval of 6.8 years) and 143 (4.0%) of WA patients (mean follow-up interval of 6.1 years). More than three-quarters of subsequent breast cancers in each subset were ductal carcinoma in situ or stage I. The 10-year probability estimate for developing TNBC was 0.56% (95% CI, 0.32%-1.0%) for AA patients and 0.25% (95% CI, 0.12%-0.53%) for WA patients. Among the 66 AA patients who developed subsequent invasive breast cancer, 16 (24.2%) developed TNBC compared with 7 (7.4%) of the 94 WA patients who developed subsequent invasive breast cancers and had complete biomarker data (P = .01). CONCLUSIONS AND RELEVANCE: This study is the largest analysis to date of TNBC in the context of racial/ethnic identity and BBD as risk factors. The study found that AA identity persisted as a significant risk factor for TNBC. This finding suggests that AA identity is associated with inherent susceptibility for TNBC pathogenetic pathways.
IMPORTANCE: Compared with white American (WA) women, African American (AA) women have a 2-fold higher incidence of breast cancers that are negative for estrogen receptor, progesterone receptor, and ERBB2 (triple-negative breast cancer [TNBC]). Triple-negative breast cancer, compared with non-TNBC, likely arises from different pathogenetic pathways, and benign breast disease (BBD) predicts future non-TNBC. OBJECTIVE: To determine whether AA identity remains associated with TNBC for women with a prior diagnosis of BBD. DESIGN, SETTING, AND PARTICIPANTS: This study is a retrospective analysis of data of a cohort of 2588 AA and 3566 WA women aged between 40 and 70 years with a biopsy-proven BBD diagnosis. The data-obtained from the Pathology Information System of Henry Ford Health System (HFHS), an integrated multihospital and multispecialty health care system headquartered in Detroit, Michigan-include specimens of biopsies performed between January 1, 1994, and December 31, 2005. Data analysis was performed from November 1, 2015, to June 15, 2016. MAIN OUTCOMES AND MEASURES: Subsequent breast cancer was stratified on the basis of combinations of hormone receptor and ERBB2 expression. RESULTS: Case management, follow-up, and outcomes received or obtained by our cohort of 2588 AA and 3566 WA patients were similar, demonstrating that HFHS delivered care equitably. Subsequent breast cancers developed in 103 (4.1%) of AA patients (mean follow-up interval of 6.8 years) and 143 (4.0%) of WA patients (mean follow-up interval of 6.1 years). More than three-quarters of subsequent breast cancers in each subset were ductal carcinoma in situ or stage I. The 10-year probability estimate for developing TNBC was 0.56% (95% CI, 0.32%-1.0%) for AA patients and 0.25% (95% CI, 0.12%-0.53%) for WA patients. Among the 66 AA patients who developed subsequent invasive breast cancer, 16 (24.2%) developed TNBC compared with 7 (7.4%) of the 94 WA patients who developed subsequent invasive breast cancers and had complete biomarker data (P = .01). CONCLUSIONS AND RELEVANCE: This study is the largest analysis to date of TNBC in the context of racial/ethnic identity and BBD as risk factors. The study found that AA identity persisted as a significant risk factor for TNBC. This finding suggests that AA identity is associated with inherent susceptibility for TNBC pathogenetic pathways.
Authors: Amanda I Phipps; Rowan T Chlebowski; Ross Prentice; Anne McTiernan; Jean Wactawski-Wende; Lewis H Kuller; Lucile L Adams-Campbell; Dorothy Lane; Marcia L Stefanick; Mara Vitolins; Geoffrey C Kabat; Thomas E Rohan; Christopher I Li Journal: J Natl Cancer Inst Date: 2011-02-23 Impact factor: 13.506
Authors: Mia M Gaudet; Michael F Press; Robert W Haile; Charles F Lynch; Sally L Glaser; Joellen Schildkraut; Marilie D Gammon; W Douglas Thompson; Jonine L Bernstein Journal: Breast Cancer Res Treat Date: 2011-06-11 Impact factor: 4.872
Authors: Tari A King; Melissa Pilewskie; Shirin Muhsen; Sujata Patil; Starr K Mautner; Anna Park; Sabine Oskar; Elena Guerini-Rocco; Camilla Boafo; Jessica C Gooch; Marina De Brot; Jorge S Reis-Filho; Mary Morrogh; Victor P Andrade; Rita A Sakr; Monica Morrow Journal: J Clin Oncol Date: 2015-09-14 Impact factor: 44.544
Authors: Evelyn Jiagge; Aisha Souleiman Jibril; Dhananjay Chitale; Jessica M Bensenhaver; Baffour Awuah; Mark Hoenerhoff; Ernest Adjei; Mahteme Bekele; Engida Abebe; S David Nathanson; Kofi Gyan; Barbara Salem; Joseph Oppong; Francis Aitpillah; Ishmael Kyei; Ernest Osei Bonsu; Erica Proctor; Sofia D Merajver; Max Wicha; Azadeh Stark; Lisa A Newman Journal: Ann Surg Oncol Date: 2016-07-28 Impact factor: 5.344
Authors: Olivia D Lara; Ying Wang; Amma Asare; Tao Xu; Hua-Sheng Chiu; Yuexin Liu; Wei Hu; Pavel Sumazin; Shitanshu Uppal; Lin Zhang; J Alejandro Rauh-Hain; Anil K Sood Journal: Cancer Date: 2019-11-15 Impact factor: 6.860
Authors: Nijole C Pollock; Johnny R Ramroop; Heather Hampel; Melissa A Troester; Kathleen Conway; Jennifer J Hu; Jo L Freudenheim; Olufunmilayo I Olopade; Dezheng Huo; Elad Ziv; Susan L Neuhausen; Patrick Stevens; Joseph Paul McElroy; Amanda Ewart Toland Journal: Breast Cancer Res Treat Date: 2022-03-14 Impact factor: 4.872
Authors: Marie E Wood; Heshan Liu; Elizabeth Storrick; David Zahrieh; H Carisa Le-Petross; Sin-Ho Jung; Patricia Zekan; M Margaret Kemeny; Jayne R Charlamb; Lili X Wang; Gary W Unzeitig; Candace S Johnson; Judy E Garber; James R Marshall; Isabelle Bedrosian Journal: Cancer Prev Res (Phila) Date: 2021-04-13
Authors: Margarite D Matossian; Alexandra A Giardina; Maryl K Wright; Steven Elliott; Michelle M Loch; Khoa Nguyen; Arnold H Zea; Frank H Lau; Krzysztof Moroz; Adam I Riker; Steven D Jones; Elizabeth C Martin; Bruce A Bunnell; Lucio Miele; Bridgette M Collins-Burow; Matthew E Burow Journal: Womens Health Rep (New Rochelle) Date: 2020-09-24